Public Consultations are held regularly as a form of soliciting public input on the draft documents produced by EUnetHTA within the framework of implementing the EUnetHTA Joint Action 2 grant agreement and 3-year EUnetHTA Joint Action 2 Work Plan. Announcements of the public consultations are made in the News section of this website.

Properly submitted contributions will be made public on the EUnetHTA public website within a month after the closing date of the public consultation (unless the author has explicitly opposed publication of their contribution or the contributions do not address the draft documents put forward for public consultation or contain complaints against institutions, personal accusations, irrelevant or offensive statements or material). The name of the author, his affiliation, and date of the submission’s receipt will be disclosed when the contribution is made public.

More detailed instructions are provided on the news dedicated for each specific public consultation.

We are happy to announce that the second Core HTA produced within the EUnetHTA Joint Action 2 Work Package 4 is available for public feedback. The topic assessed is “Use of Intravenous immunoglobulins for Alzheimer’s disease including Mild Cognitive Impairment”
We are pleased to announce that as of today the Draft Project Plan “Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke”, produced within WP5 Strand B, has entered the public consultation phase.
In order to gather as much feedback as possible, WP7 Subgroup 2 has decided to extend the public consultation period on the Position paper on how to decide on the appropriate study design until May 29, 2015 at 12:00 noon CET.
Deadline extended – Public consultation on the Position paper on how to best formulate research recommendations for primary research arising from HTA reports.
We are pleased to announce that as of today, 20 April, 2015, the draft methodological guideline “Internal validity of non-randomised studies (NRS) on interventions”, produced within WP7 - Subgroup 3, has entered the public consultation phase.